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Protein microarrays: a chance to study microorganisms?
Received: 4 October 2005 / Revised: 23 December 2005 / Accepted: 24 December 2005 / Published online: 18 February 2006
# Springer-Verlag 2006
Abstract Within the last 5 years, protein microarrays have
been developed and applied to multiple approaches:
identification of protein–protein interactions or protein–
small molecule interactions, cancer profiling, detection of
microorganisms and toxins, and identification of antibodies
due to allergens, autoantigens, and pathogens. Protein
microarrays are small size (typically in the microscopy slide
format) planar analytical devices with probes arranged in
high density to provide the ability to screen several hundred
to thousand known substrates (e.g., proteins, peptides,
antibodies) simultaneously. Due to their small size, only
minute amounts of spotted probes and analytes (e.g.,
serum) are needed; this is a particularly important feature,
for these are limited or expensive. In this review, different
types of protein microarrays are reviewed: protein micro-
arrays (PMAs), with spotted proteins or peptides; antibody
microarrays (AMAs), with spotted antibodies or antibody
fragments (e.g., scFv); reverse phase protein microarrays
(RPMAs), a special form of PMA where crude protein
mixtures (e.g., cell lysates, fractions) are spotted; and
nonprotein microarrays (NPMAs) where macromolecules
other than proteins and nucleic acids (e.g., carbohydrates,
monosaccharides, lipopolysaccharides) are spotted. In this
study, exemplary experiments for all types of protein arrays
are discussed wherever applicable with regard to investiga-
tions of microorganisms.
Introduction
Protein microarrays have been developed within the last
5 years using the knowledge and technical innovations
developed for DNA microarrays. DNA microarray tech-
nology has evolved, as a consequence to handle sets of
thousands of probes from the huge sequencing programs,
beginning with microbial genomes (Sanger et al. 1982;
Fleischmann et al. 1995) and reaching the top with the
mouse (Nadeau et al. 2001) and the human (Venter et al.
2001) genomes. The technical aspect of miniaturizing
traditional methods, such as Western-Blotting and protein
dotting onto classical surfaces such as nitrocellulose and
nylon membranes could be adapted to protein microarray
technology.
First protein arrays were constructed as high-density
protein arrays to analyze protein expression cDNA
libraries (Bussow et al. 1998). These arrays bear the
feature of high-density (112 spots/cm2) but have a format
of about 500 cm2, and therefore were called protein
macroarrays. In this way, 27,648 E. coli clones were
spotted in duplicate onto one 222×222 mm Nylon filter
membrane (Hybond-N+, Amersham). Subsequently, pro-
tein-expression and the detection of recombinant expres-
sion products were performed directly on these filters,
without further purification.
In a further development of this high-density spotting,
crude cell lysates or purified proteins were spotted onto
PVDF filters cut to microscopic slide format. This way,
protein microarrays were generatedwith a theoretical density
of 300 spots/cm2. In this study, a detection limit could be
reached for spotted GAPDH protein detected by a mono-
clonal anti-GAPDH antibody of 250 amol/spot, respectively,
10 pg/spot (Lueking et al. 1999).
A Short time later, two publications demonstrating the
potential of protein microarrays to screen whole proteomes
were presented. The first proteome wide-protein array was
used to analyze protein–protein interactions of Saccharo-
myces cerevisiae proteins. This array consisted of 6,000
yeast transformants, each with one cloned ORF fused to an
activation domain and screened with 192 different yeast
proteins (Uetz et al. 2000). This approach is from the
technical aspect of in situ expression similar to the work of
Bussow et al. (1998). The second proteome wide protein
microarray consisted of 5,800 unique yeast proteins on a
modified microscopic slide, which bear all adjectives of a
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protein-microarray. With this array, they demonstrated the
usability of protein microarray technology to screen for
protein–protein interactions by identification of calmodu-
lin- and phospholipid-binding proteins (Zhu et al. 2001).
While these exemplary studies belong to the group of
protein microarrays (PMAs) discussed below, they repre-
sent pioneer works in the field of all protein microarrays.
The types of protein microarrays
Protein microarrays (PMAs)
PMAs are named after the spotted compound basically
purified recombinant proteins or peptides. These compo-
nents can be used for a broad range of applications and
some of them are discussed in this section.
A common application of PMAs is the detection of
antibody reactions (e.g., serum screening), which was used
in several applications for human (Lueking et al. 2003),
bacterial (Li et al. 2005; Steller et al. 2005) or plant proteins
(Kersten et al. 2003). The systematical search for antibody
specificities and cross-reactivities, as done for eleven
polyclonal and monoclonal antibodies on PMAs contain-
ing 5,000 yeast proteins is an alternative strategy (Michaud
et al. 2003).
Furthermore, PMAs can be used for the high-throughput
identification of kinase targets, to identify, e.g., potential
substrates for, e.g., Arabidopsis thaliana mitogen-activated
protein kinases (MPK). For this purpose, a novel method,
allowing high throughput study of protein phosphorylation
was used on a microarray including 1,690 nonredundant
Arabidopsis proteins. Using a threshold-based quantification
method to evaluate the microarray results, 48 potential
substrates of MPK3, and 39 of MPK6 could be identified; of
which, 26 are common for both kinases (Feilner et al. 2005).
Polypeptides, protein domains or in general not complete
proteins can be spotted as well to generate PMAs. Peptide
microarrays can be used for the detection of molecular
interactions in cellular signal transduction (Stoevesandt et
al. 2005). Therefore, phosphorylated CD3ζ ITAM and the
nonphosphorylated counterpart ITAM peptides were
spotted onto silanizated glass surfaces and incubated with
lysates of cells expressing a fusion protein of the interaction
partner ZAP-70.
Peptide microarrays were also used for simultaneous
detection of pathogen infection. For this purpose, peptides,
specific for hepatitis B and C viruses, human immunode-
ficiency virus, Epstein Barr virus, and syphilis were made
functional by a glyoxyl group and anchored on the glass
surface by site-specific α-oxosemicarbazene ligation. This
combined assay displays high sensitivity and specificity
(Duburcq et al. 2004).
Peptide microarrays are perfectly suited for epitope
mapping of antibodies and antibody fragments: A set of
peptides with N- and C-terminal truncations of the peptide
of interest were spotted to aldehyde slides (Poetz et al.
2005). The authors have introduced quantifier spots to
perform a relative affinity ranking of recombinant Fab
fragments. For this system, two spots are required: One
spot contains the antigen, while the other a capture mole-
cule, which recognizes the constant part of the Fab (Poetz
et al. 2005). Affinity values are calculated from both signal
intensities using the ambient analyte assay conditions first
defined by Ekins 1989.
Reverse phase microarrays (RPMAs)
Reverse phase microarrays (RPMAs) are a special form of
PMA, because here, protein mixtures derived from cell or
tissue lysates are spotted. This approach offered the
possibility to analyze modified proteins, which can not
be obtained from E. coli or yeast. The first RPMAwas used
to quantify the abundance of selected proteins during the
progression of normal epithelium into prostate carcinoma
(Paweletz et al. 2001). Cancer profiling is a predominant
application of RPMAs identifying, for instance, potential
serum markers for colon cancer (Nam et al. 2003). In this
study, fractionated, solubilized proteins from the LoVo
colon cancer cell line were arrayed and incubated with
autoantibodies of the same patient. Subsequently, protein
fractions were selected and the proteins within the fractions
identified by MS analysis.
Furthermore, RPMAs can be used to simultaneously
monitor dynamics of the site-specific phosphorylation of
signaling molecules during stimulation of Jurkat T-Cells
(Chan et al. 2004). The authors determined a dynamic
range of four orders of magnitude with a detection limit of
one protein in 105 to 106 lysate proteins.
Reproducible protein quantification can be obtained by
multiple replica and dilution series on the array (Mircean et
al. 2005). Until now, RPMAs for analyzing microorgan-
isms have not been published, and RPMAs are discussed in
more detail elsewhere (Hultschig et al. 2006).
Antibody microarrays (AMAs)
Antibody microarrays (AMAs) consists of antibodies or
antibody fragments. They are used for, e.g., the identifi-
cation of proteins and bacteria. For example, biotinylated
capture antibodies are immobilized on NeutrAvidin-coated
slides and after incubation with solutions containing toxins
or bacteria, these are detected by subsequent incubation
with fluorescently labeled secondary antibodies. The
detection limits in the case of the tested cholera toxin,
staphylococcal enterotoxin B, Ricin, and Bacillus globigii
were as low as 8, 4, 10 ng/ml and 6.2×104 cfu/ml, re-
spectively (Delehanty and Ligler 2002).
Furthermore, AMAs are useful tools for analyzing
protein content, and its changes due to development,
disease, signaling, and other factors. Such an analysis was
performed with an AMA consisting of 224 different
antibodies on a nitrocellulose-coated glass slide, probed
with protein extracts of mouse F9 embryonic carcinoma
cells stimulated to differentiate and 43 proteins were
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identified to be upregulated and a sensitivity of 3 ng/ml
protein detection was reached (Kopf et al. 2005).
In a different study, 378 antibodies containing commer-
cial microarray (BD Bioscience) was applied to profile the
effect of OxLDL (oxidized low density lipoprotein) on
human aortic smooth muscle cells. Out of the 298 detected
proteins in the cell lysates, 54 were differentially expressed
(Sukhanov and Delafontaine 2005).
Besides the antibodies, antibody fragments such as scFv’s
can be used to generate AMAs. However, although the
approach is particularly interesting, the bottleneck in
analyzing proteins and tissues is the availability of suitable
antibodies. To overcome this bottleneck, in vitro selection
methods such as phage display were implemented (Konthur
et al. 2005). To advance the effectiveness of the in vitro
selection, scFv’s can be spotted directly onto microarrays
(Wingren et al. 2005) or analyzed by doublespotting the scFv
directly onto the prior insolublezed target proteins (Ange-
nendt et al. 2004).
Non-protein microarrays (NPMAs)
Besides proteins (or nucleic acids), other components can be
spotted to surfaces that bind proteins or microorganisms.
Although these are not protein microarrays, they are
Table 1 Surface and applications
Surface Type Application Reference
Aldehyde PMA Epitope mapping using peptide microarrays. (Poetz et al. 2005)
Amine AMA Comparison study of some monoclonal or polyclonal antibodies on different surfaces. (Angenendt et al.
2002)
Aminosilane NPMA Detection of tetanus and cholera toxins using monosaccharide arrays. (Ngundi et al. 2005)










Proteins/peptides bind via a cellulose binding protein to a cellulose-coated surface. Also
good results with unpurified proteins or antibodies.
(Ofir et al. 2005)
Copolymer AMA Assay for rheumatoid factor. The detection limit was 54 amol/spot. (Cretich et al. 2004)
DNA-coating PMA Binding of proteins via a GAL4 DNA binding domain on a DNA-coated surface. (Choi et al. 2005)
Epoxy PMA/
NPMA
Serological tuberculosis assay. (Tong et al. 2005)
NAPPA PMA/
AMA
Cell-free protein expression directly on microarray, subsequent to capture antibodies. With
this interaction studies of recombinant human proteins.
(Ramachandran et al.
2004)
NC FAST AMA Protein levels from different cell types were analyzed on AMA containing 224 different
antibodies. Detection of 3 ng/ml Caspase 9.
(Kopf et al. 2005)
NC FAST PMA First bacterial protein microarray used for N. meningitidis serum screening. (Steller et al. 2005)
NC FAST AMA Analysis of antibody specificities on yeast proteome arrays. (Michaud et al.
2003)
NC FAST RPMA Signal transduction analysis of cell culture lysates. Spot size 400 μm. (Chan et al. 2004)
NC NPMA Lipopolysaccharide spotted on NC to detect bacterial species-specific antibodies. (Thirumalapura et al.
2005)
Ni-coated PMA 5,800 yeast proteins spotted for interaction screen with other proteins and phospholipids. (Zhu et al. 2001)
Octyltri-
chlorosilane
PMA Protein binding via leucine zipper with UV crosslinking. (Zhang et al. 2005)
Polyacrylamide PMA First plant protein microarray used for antibody reactions. (Kersten et al. 2003)
Poly-L-Lysine AMA/
PMA
Investigation of 115 antibody/antigen pairs. (Haab et al. 2001)
PS modified AMA Comparison study of some monoclonal or polyclonal antibodies on different surfaces. (Angenendt et al.
2002)
Silicon AMA Anti rabbit IgG was spotted and detected with rabbit IgG-FITC. They reach by small spots
sizes (55 μm) a theoretical density of 4,400 spots/cm2.
(Ressine et al. 2003)
Sol–Gel AMA Detection of a pathogenic E. coli strain using specific antibodies. (Lee et al. 2005)
Streptavidin AMA Orientated binding of antibodies and Fab fragments on streptavidin-coated AMA.
Theoretical density of 10,000 spots/cm2.
(Peluso et al. 2003)
Here, some surfaces are listed with their classification and applications. NC nitrocellulose (Super Nitro, Telechem International, USA); NC
FAST nitrocellulose coated FAST slides (Schleicher&Schuell, Germany); PS polystyrol; PMA protein microarray; AMA antibody
microarray; RPMA reverse phase protein microarray; NPMA non-protein microarray; NAPPA nucleic acid programmable protein array
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nevertheless presented here because of their similar applica-
tion possibilities.
The first example is a NPMA containing carbohydrates,
which was subsequently probed with different E. coli
strains. E. coli cells were bound by adhesion to mannose
spotted on the microarray. An advantage of this approach is
the nondestructive nature of this technique because the
microorganisms could be recovered and used for further
investigations, e.g., antibacterial susceptibility or substrate
acquisition tests. In this study, the bacteria were stained
using a nucleic acid dye and routinely 109E. coli cells were
used for detection, but the limit observed was 105–106 cells
(Disney and Seeberger 2004).
Another example for a NPMA is a monosaccharide array
for the detection of bacterial toxins. Arrays of N-acetyl
galactosamine (GalNAc) or N-acetylneuraminic acid
(Neu5Ac) derivates were immobilized on the surface and
used as receptors. The bacterial toxins (cholera and tetanus)
were bound specifically to the monosaccharides, whereas
labeled cells of E. coli, Salmonella typhimurium, Listeria
monocytogenes, or staphylococcal enterotoxin B were not
bound. For both toxins, the limit of detection is around
100 ng/ml (Ngundi et al. 2005).
In another experiment, lipopolysaccharide (LPS)
microarray were used for the detection of antibodies
(Thirumalapura et al. 2005). Therefore, LPS was isolated
from different bacteria and immobilized on nitrocellu-
lose-coated glass slides. The specificity of these LPS
arrays was tested using four monoclonal antibodies
against these bacteria and the detection limit for
antibodies was 10 ng/ml.
Limitations and solutions of protein microarray
technology
Besides the obvious advantages of protein microarrays, such
as high-throughput, high-density, improved reproducibility,
and low sample consumption, there are also some limitations
and bottlenecks. In this part of the review, I discuss more
general aspects applicable to all protein microarrays.
Availability of purified proteins
The on demand availability of purified proteins is in the
case, were hundred to thousands proteins should be spotted
a major limitation.
A very fascinating approach to circumvent this limita-
tion was done by Ramachandran et al.(2004). They have
generated protein microarrays by printing cDNAs onto
glass slides besides capture antibodies (anti-GST). After
adding a cell-free expression system, the proteins were
generated directly on the microarray and bound with the
fused GST-part to the capture antibodies. The proteins
could now be analyzed as in a conventional protein-
microarray. They demonstrated the feasibility with specific
antibody binding to distinct fusion proteins and to map
pairwise interactions among 29 human DNA replication
proteins (Ramachandran et al. 2004).
To circumvent purification it might be useful for some
applications to spot unpurified proteins if possible. In a
recent approach, a cellulose surface was used and proteins
were bound indirectly via a cellulose binding protein (Ofir
et al. 2005).
A further possibility to circumvent the limitation of
availability of purified and/or modified proteins is the
RPMA approach presented above.
Availability of suitable surfaces
Proteins are, due to their composition from many different
amino acids, a class of very heterogeneous macromole-
cules with variable properties. This makes it extremely
complicated to find a common surface suitable for different
proteins with a broad range in molecular weight and
physico–chemical properties such as charge and hydro-
phobicity. Therefore, multiple surfaces have been devel-
oped during the last 5 years; some of them are listed in
Table 1 with their applications. Thereby, it is not important
if the binding is due to a covalent binding or a physical
adsorption. Binding could be from chemical reactions or
physical adsorption directly between the surface structures
and the spotted molecule (protein/antibody), or indirectly
by a linker molecule. This linker molecule can be part of
the protein (fusion protein) or a separate molecule.
To find a surface suitable for all spotted components in a
project is a major challenge, and there is more than one
recommendation to use a distinct surface, and only few
publications are dealing with this aspect, globally. Most
investigations are driven by a discrete scientific problem,
and for this problem-optimized conditions for this special
approach have been found to obtain results. From this
reason, available data are often not conferrable because
they are different in the spotted material (e.g., different
proteins), in analytes (diverse sera, proteins), and are
spotted on different surfaces, and processed under different
conditions. However, the few systematic studies for finding
optimal processing conditions and suitable surfaces
(Angenendt et al. 2002, 2003a,b; Gutmann et al. 2005)
are often without a study-driven relevance.
Orientation of spotted components
A further aspect is the orientation of spotted compounds.
For some applications where sufficient amounts of reactive
parts (e.g., antigenic epitopes or proteins on the surface of a
spotted microorganism) are present, this aspect is of less
relevance. For others, like quantitative analysis, enzymatic
reactions, interaction studies, phosphorylations, or protein
drug screens, it becomes of essential relevance because
reactive sites of proteins are usually limited.
The effect of randomly vs specifically oriented capture
agents based on both full-sized antibodies and Fab
fragments on two types of streptavidin-coated slides was
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studied (Peluso et al. 2003). The orientation of capture
agents increases the analyte-binding capacity up to 10-fold.
By using surface plasmon resonance analysis, a dense
monolayer of 90% active Fab fragments has been detected
(Peluso et al. 2003).
This aspect has also been studied for enzymatic activity
because activity can be completely lost or lowered (Cha et
al. 2005). A different approach is the linking of proteins to
DNA-coated arrays mediated from PCR-amplified DNA to
a GAL4 DNA binding domain (Choi et al. 2005).
A new method for stable binding of proteins to a surface
has recently been developed by linking proteins via a Leucine
zipper (Zhang et al. 2005). Therefore an elastin mimetic
domain is covalently bound to anOctyltrichlorosilane surface
by a photoreactive amino acid and UV irradiation, whereas
the target protein is fused to the complementary leucine
zipper helix. The strong noncovalent binding of the helices
leads to effective immobilizing of the target protein.
Sensitivity and detection limit
Sensitivity and specificity are also very important features
which are linked to other parameters like signal to noise
ratio, background, and binding of (serum)–proteins to the
background. These parameters are not only influenced by
the surface; processing and detection also affect them. The
detection limit is a good way to measure parameter, but is
in most cases only a value for a certain couple of action
partners (e.g., protein-antibody), and often detected only
for an individual experimental setup.
Conventional detectionmethods for microarrays often use
fluorescent dyes, which were detected by irradiation from a
laser scanner. Detection methods are discussed intensively
elsewhere (Espina et al. 2004; Feilner et al. 2004), while in
this study, only new approaches should be pointed out to
reach much higher sensitivities. With a special method called
MIST (multiple spotting technique) (Angenendt et al. 2003a,
b), multiple spotting steps are performed successively to
one position. In such an experiment, protein is spotted in the
first spotting round, and after washing and blocking steps,
the corresponding antibody was spotted in the second
spotting round to the same position. By this technique, it is
possible to perform an enzymatic reaction and reach with this
approach an extremely high sensitivity of 60 ymol (10−24mol)
(Angenendt et al. 2005) because chemical reactions take
place in small “reaction compartments” formed by droplets.
Normally enzymatic reactions, producing soluble products,
were not possible on conventional protein microarrays, as
products could mix on the planar surface.
A further technical approach for better sensitivity is the
rolling circle amplification (RCA) (Lizardi et al. 1998). The
system requires the direct conjugation of the proteins to be
analyzed with a label (e.g., biotin or digoxigenin). This label
was detected by an antibody, which is bound to a primer. After
hybridization of a circular DNA molecule, the primer is
extended by a polymerase. For detection, fluorescently labeled
oligonucleotides complementary to the elongated DNAwere
used. AMAs consisting of 84 distinct antibodies specific to
serum proteins were used with detection via RCA, for protein






Fig. 1 Possible identification of microorganisms. Microorganisms
(dark blue symbols) will be fixed directly to coated microarrays
(possible species-specific monosaccharides; light green in a and b).
Alternatively, microorganisms can be bound via species-specific
antibodies (black Ys in c–e). Direct detection with species-specific
labeled antibodies (black Ys in a and c), sandwich assays with
species-specific antibodies (black Ys), and secondary labeled
antibodies (brown Ys with red or green stars in b and d) could be
performed. With the MIST technology (Angenendt et al. 2003a,b),
detection could be performed by using an antibody bound enzyme
(blue circle bound to Ys) which activity converts a substrate (yellow)
to a detectable product (green or red circle in e)
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Stability of spotted compounds
Very important for use, e.g., in diagnosis is the stability of
diagnostic protein microarray test systems. Two kinds of
stability have to be distinguished: one is the stability of the
surface itself, and the other is the stability of spotted
proteins on these. In a stability analysis, different
antibodies were spotted on four different surfaces and
stored under two different conditions (4°C, dried or in
blocking solution) over 8 weeks, without crucial differ-
ences (Angenendt et al. 2002). A shelf life was detected of
more than 1 year at 2–8°C for a RheumaChip, with 14
different autoantigens suitable for the simultaneous deter-
mination of the most significant autoantibodies associated
with rheumatic diseases (Schulte-Pelkum et al. 2005).
Multiplexing
With protein microarrays, multiple (up to several thou-
sands) spotted compounds can be analyzed, but in most
applications only with one single analyte or a mixture of
few at one time. With multiplexing approaches, multiple
analytes should also be investigated at the same time.
Multiplexing is an aspect not important for all approaches,
but for approaches where many probes should be screened
(e.g., medical routine diagnosis), it becomes of tremendous
importance. Recently, the aspect of multiplexing has been
discussed in detail (Kersten et al. 2005), pointing out two
major strategies: One is the multiplexing by different
fluorophores, but this approach enables multiplexing with
the limitation of detectable labels on the microarray. This
approach could be performed better with nonarray systems,
like the LiquiChip system of Qiagen. The second approach
is to perform multiplexing by compartmentation, with
physical compartments as multiwell slides (from different
manufactures) or nonphysical compartmentation by MIST
(Angenendt et al. 2003a,b, 2004, 2005).
Microarrays and microorganisms
Besides the general applications of protein microarrays
mentioned above, there are only a few publications dealing
with microorganisms. In this section, some exemplary
publications in the field of microbiology are presented,
dealing with protein microarrays and possible detection
methods are summarized in Fig. 1.
The first PMA used for serodiagnosis of infectious
disease contained a dilution row of human IgG (2–50 pg)
and IgM (0.4–8 pg), and antigens (50 pg) from Toxoplasma
gondii, rubella virus, cytomegalovirus, and herpes simplex
virus type I and II spotted on amino–silane-activated glass
slides (Mezzasoma et al. 2002). The analysis showed a
linear detection of internal calibration curves (IgG and
IgM) and antigens, respectively, and results similar to
ELISA analysis.
In my group, we have performed serum-screening ex-
periments with serum probes from Meningitis patients on
PMAs with 67 different recombinant Neisseria proteins.
From these proteins coding from phase variable genes, 47
showed an immune response to at least one out of 20
patient sera. Nine proteins elicited an immune response in
more than three patients, and the phase-variable opacity
protein OpaV, showing responses in 11 patient sera. This is
also an interesting aspect as this protein is annotated as a
hypothetical protein with an authentic frameshift from the
Neisseria genome. So protein microarray technology could
be used to verify predictions from genome data (Steller et
al. 2005).
Another bacterial PMA containing about 150 Yersinia
pestis proteins was used to profile antibody responses in
immunized rabbits. In this study, antibodies to 50 proteins
could be detected. Out of these 11 proteins are F1 and V
antigens to which the predominant antibody responses
occurred. These identified targets could be used for further
evaluation as candidates for vaccines and as diagnostic
markers (Li et al. 2005).
PMAs for serum screening of bacterial proteins have been
established as shown above, and the use of viral proteins
instead of bacterial proteins is technically not a difference,
and could be used for identification and classification of
viruses.
Recently, PMAs were used for investigation of a
coronavirus, the severe acute respiratory syndrome coro-
navirus (SARS-CoV). An important step in the develop-
ment of vaccines and of diagnostic markers is to profile the
antibodies to individual proteins. In this study, 13 recom-
binant proteins associated with structural and putative
uncharacterized proteins of the SARS-CoV were prepared
and used for the generation of SARS-CoV PMA. These
were subsequently screened with SARS patient sera for
their IgG antibodies, and antibody reactions to some of
these proteins could be observed and found in one im-
munogenic protein as a good vaccine candidate. Moreover,
they identified potential diagnostic markers and could
support a hypothesis for some of the proteins to be
synthesized during virus cycle deduced from the presence
of antibodies against these (Qiu et al. 2005).
A PMA/NPMA array, consisting of 54 different Myco-
bacterium tuberculosis antigens, was used for a serological
tuberculosis (TB) assay (Tong et al. 2005). This array
consists of recombinant antigens, purified polysaccharides
and lipopolysaccharides, oligosaccharides bound to bovine
serum albumin, and antigens from fractionation of M.
tuberculosis cells and culture fluids, spotted on epoxy-
coated slides. This array could be stored at 4°C for 7 weeks.
One antigen, Ara6-BSA, discriminated well between TB
and non-TB, whereas most antigens gave poor discrimi-
nation, due to E. coli protein contamination or lack of
glycosylation in E. coli.
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Conclusions
In this review, protein microarray technology is presented
from the beginning to recent applications. Protein micro-
arrays were divided in the major groups of PMA, RPMA
and AMA, and the NPMA approaches. Limitations of
protein microarray technology and possible solutions are
discussed, and the use of protein microarrays for studying
microorganisms is pointed out.
Until now, there are only limited advances in the
identification of microorganisms using protein microar-
rays. A major limitation is, until now, the high detection
limit that could be reached, but there has been some new
technological advancement. Fortunately, there are some
encouraging approaches in indirect identification of patho-
genic interactions by identifying serum antibodies. But this
is only the matter of time that protein microarrays and, here
especially, antibody-microarrays will be used for identifi-
cation. This will be done first for in vitro models, but the
most important are the identification of pathogens in
medical samples (e.g., stool, blood, other body fluids) and
from environmental sources (e.g., soil, air filtrates). These
two fields will benefit from the addressed problems from
the personalized medicine as well as from aspects coming
from bioterrorism. So, one could expect in the near future
that protein microarrays will be established for many
applications in microbiological investigation.
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